Cipla gets CDSCO panel green signal to conduct Paxlovid trials in India

Published On 2022-02-28 06:40 GMT   |   Update On 2022-02-28 06:40 GMT
Advertisement

In a significant development, drug-major Cipla has got a green signal from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct local trials on the anti-Covid-19 pill Paxlovid.

The SEC of the Central Drugs Standard Control Organization has granted Cipla permission to perform bioavailability and bioequivalence (BA/BE) trials for the anti-Covid-19 pill Paxlovid, as per the report published by ET.

For more information, check out the full story on the link below:

Cipla gets CDSCO panel nod to conduct Indian trials of Paxlovid


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News